CA2986891A1 - Compositions et methodes pour le traitement de la maladie de parkinson et de troubles associes - Google Patents

Compositions et methodes pour le traitement de la maladie de parkinson et de troubles associes Download PDF

Info

Publication number: CA2986891A1
Authority: CA; Canada
Prior art keywords: tapentadol; disease; dopa; pharmaceutical composition; parkinson
Prior art date: 2015-05-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

CA2986891A

Other languages

English (en)

Other versions

CA2986891C (fr

Inventor

Nuno AFONSO

Sara SOUSA

Rita VAZ

Diana CHAPELA

Sofia Corte-Real

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA

Technophage Investigacao e Desenvolvimento em Biotecnologia SA

Lusomedicamenta SA

Original Assignee

LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA

Technophage Investigacao e Desenvolvimento em Biotecnologia SA

Lusomedicamenta SA

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-26

Filing date

2016-05-25

Publication date

2016-12-01

2016-05-25 Application filed by LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA, Technophage Investigacao e Desenvolvimento em Biotecnologia SA, Lusomedicamenta SA filed Critical LABORATORIO MEDINFAR-PRODUTOS FARMACEUTICOS SA

2016-12-01 Publication of CA2986891A1 publication Critical patent/CA2986891A1/fr

2022-01-04 Application granted granted Critical

2022-01-04 Publication of CA2986891C publication Critical patent/CA2986891C/fr

Status Active legal-status Critical Current

2036-05-25 Anticipated expiration legal-status Critical

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 286
239000000203 mixture Substances 0.000 title claims abstract description 63
208000018737 Parkinson disease Diseases 0.000 title claims abstract description 32
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims abstract description 264
KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 claims abstract description 255
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims abstract description 252
229960005126 tapentadol Drugs 0.000 claims abstract description 247
229960004502 levodopa Drugs 0.000 claims abstract description 217
201000010099 disease Diseases 0.000 claims abstract description 182
230000000694 effects Effects 0.000 claims abstract description 116
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 114
238000000034 method Methods 0.000 claims abstract description 108
238000011282 treatment Methods 0.000 claims abstract description 99
208000024891 symptom Diseases 0.000 claims abstract description 89
239000003795 chemical substances by application Substances 0.000 claims abstract description 78
239000003136 dopamine receptor stimulating agent Substances 0.000 claims abstract description 53
229940005501 dopaminergic agent Drugs 0.000 claims abstract description 42
230000005021 gait Effects 0.000 claims abstract description 42
208000035475 disorder Diseases 0.000 claims description 100
ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 claims description 88
229960004143 tapentadol hydrochloride Drugs 0.000 claims description 87
208000012661 Dyskinesia Diseases 0.000 claims description 67
230000008014 freezing Effects 0.000 claims description 41
238000007710 freezing Methods 0.000 claims description 41
230000033001 locomotion Effects 0.000 claims description 36
230000006735 deficit Effects 0.000 claims description 31
238000009472 formulation Methods 0.000 claims description 27
208000019901 Anxiety disease Diseases 0.000 claims description 19
230000036506 anxiety Effects 0.000 claims description 18
239000012729 immediate-release (IR) formulation Substances 0.000 claims description 18
206010030312 On and off phenomenon Diseases 0.000 claims description 14
206010012239 Delusion Diseases 0.000 claims description 13
206010012289 Dementia Diseases 0.000 claims description 13
231100000868 delusion Toxicity 0.000 claims description 13
TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 claims description 12
239000003937 drug carrier Substances 0.000 claims description 12
229960004380 tramadol Drugs 0.000 claims description 12
TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 claims description 12
208000004547 Hallucinations Diseases 0.000 claims description 11
208000028698 Cognitive impairment Diseases 0.000 claims description 10
208000010877 cognitive disease Diseases 0.000 claims description 10
230000002829 reductive effect Effects 0.000 claims description 10
208000009017 Athetosis Diseases 0.000 claims description 9
206010008748 Chorea Diseases 0.000 claims description 9
208000012601 choreatic disease Diseases 0.000 claims description 9
230000003111 delayed effect Effects 0.000 claims description 9
208000001089 Multiple system atrophy Diseases 0.000 claims description 8
206010031127 Orthostatic hypotension Diseases 0.000 claims description 8
208000028017 Psychotic disease Diseases 0.000 claims description 8
230000009184 walking Effects 0.000 claims description 8
206010027951 Mood swings Diseases 0.000 claims description 6
230000001144 postural effect Effects 0.000 claims description 5
206010003840 Autonomic nervous system imbalance Diseases 0.000 claims description 4
230000005856 abnormality Effects 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 4
238000002156 mixing Methods 0.000 claims description 4
206010006100 Bradykinesia Diseases 0.000 claims description 2
208000014094 Dystonic disease Diseases 0.000 claims description 2
208000006083 Hypokinesia Diseases 0.000 claims description 2
208000010118 dystonia Diseases 0.000 claims description 2
XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 abstract description 138
229960001203 stavudine Drugs 0.000 abstract description 134
239000003814 drug Substances 0.000 abstract description 108
229940079593 drug Drugs 0.000 abstract description 80
BLXXJMDCKKHMKV-UHFFFAOYSA-N Nabumetone Chemical compound C1=C(CCC(C)=O)C=CC2=CC(OC)=CC=C21 BLXXJMDCKKHMKV-UHFFFAOYSA-N 0.000 abstract description 61
229960004270 nabumetone Drugs 0.000 abstract description 58
239000013543 active substance Substances 0.000 abstract description 45
150000003839 salts Chemical class 0.000 abstract description 26
210000002569 neuron Anatomy 0.000 abstract description 18
208000015122 neurodegenerative disease Diseases 0.000 abstract description 10
238000002483 medication Methods 0.000 abstract description 5
230000001918 neurorescue Effects 0.000 abstract description 4
230000032683 aging Effects 0.000 abstract description 3
230000004112 neuroprotection Effects 0.000 abstract description 3
238000012360 testing method Methods 0.000 description 102
241001465754 Metazoa Species 0.000 description 86
230000001225 therapeutic effect Effects 0.000 description 58
239000007924 injection Substances 0.000 description 54
238000002347 injection Methods 0.000 description 54
241000699670 Mus sp. Species 0.000 description 51
108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 44
102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 44
238000011084 recovery Methods 0.000 description 41
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 40
230000006399 behavior Effects 0.000 description 39
230000017311 musculoskeletal movement, spinal reflex action Effects 0.000 description 37
208000015592 Involuntary movements Diseases 0.000 description 36
241000252212 Danio rerio Species 0.000 description 33
230000000069 prophylactic effect Effects 0.000 description 32
150000001875 compounds Chemical class 0.000 description 31
239000003826 tablet Substances 0.000 description 31
210000004027 cell Anatomy 0.000 description 28
230000002354 daily effect Effects 0.000 description 26
239000002775 capsule Substances 0.000 description 25
230000001684 chronic effect Effects 0.000 description 25
239000000243 solution Substances 0.000 description 24
210000002683 foot Anatomy 0.000 description 22
230000001965 increasing effect Effects 0.000 description 22
241000700159 Rattus Species 0.000 description 20
229960003638 dopamine Drugs 0.000 description 20
238000004458 analytical method Methods 0.000 description 19
210000004556 brain Anatomy 0.000 description 19
230000006727 cell loss Effects 0.000 description 18
230000003902 lesion Effects 0.000 description 18
206010044565 Tremor Diseases 0.000 description 17
230000004044 response Effects 0.000 description 17
229940124597 therapeutic agent Drugs 0.000 description 17
238000002474 experimental method Methods 0.000 description 16
230000006698 induction Effects 0.000 description 16
238000001990 intravenous administration Methods 0.000 description 15
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 14
208000012902 Nervous system disease Diseases 0.000 description 14
210000005064 dopaminergic neuron Anatomy 0.000 description 14
231100000673 dose–response relationship Toxicity 0.000 description 14
230000003137 locomotive effect Effects 0.000 description 14
230000004770 neurodegeneration Effects 0.000 description 14
239000003981 vehicle Substances 0.000 description 14
210000001577 neostriatum Anatomy 0.000 description 13
238000002560 therapeutic procedure Methods 0.000 description 13
210000003050 axon Anatomy 0.000 description 12
239000002207 metabolite Substances 0.000 description 12
239000000843 powder Substances 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 11
102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 11
230000008901 benefit Effects 0.000 description 11
238000010172 mouse model Methods 0.000 description 11
238000012346 open field test Methods 0.000 description 11
230000000384 rearing effect Effects 0.000 description 11
238000010171 animal model Methods 0.000 description 10
230000003376 axonal effect Effects 0.000 description 10
230000037396 body weight Effects 0.000 description 10
238000001802 infusion Methods 0.000 description 10
RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 description 10
231100000419 toxicity Toxicity 0.000 description 10
230000001988 toxicity Effects 0.000 description 10
241000282472 Canis lupus familiaris Species 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
238000010521 absorption reaction Methods 0.000 description 9
238000003556 assay Methods 0.000 description 9
238000009227 behaviour therapy Methods 0.000 description 9
230000008030 elimination Effects 0.000 description 9
238000003379 elimination reaction Methods 0.000 description 9
238000013265 extended release Methods 0.000 description 9
210000003194 forelimb Anatomy 0.000 description 9
230000009467 reduction Effects 0.000 description 9
208000019116 sleep disease Diseases 0.000 description 9
241001573498 Compacta Species 0.000 description 8
102100036279 DNA (cytosine-5)-methyltransferase 1 Human genes 0.000 description 8
241000282412 Homo Species 0.000 description 8
230000003542 behavioural effect Effects 0.000 description 8
230000008499 blood brain barrier function Effects 0.000 description 8
210000001218 blood-brain barrier Anatomy 0.000 description 8
230000007423 decrease Effects 0.000 description 8
230000007850 degeneration Effects 0.000 description 8
229940052760 dopamine agonists Drugs 0.000 description 8
230000001771 impaired effect Effects 0.000 description 8
230000000324 neuroprotective effect Effects 0.000 description 8
229960000245 rasagiline Drugs 0.000 description 8
239000011780 sodium chloride Substances 0.000 description 8
239000000126 substance Substances 0.000 description 8
210000003523 substantia nigra Anatomy 0.000 description 8
241000251468 Actinopterygii Species 0.000 description 7
DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 7
241000699666 Mus <mouse, genus> Species 0.000 description 7
239000011668 ascorbic acid Substances 0.000 description 7
229960005070 ascorbic acid Drugs 0.000 description 7
235000010323 ascorbic acid Nutrition 0.000 description 7
239000008280 blood Substances 0.000 description 7
238000009826 distribution Methods 0.000 description 7
JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 description 7
230000001976 improved effect Effects 0.000 description 7
230000006872 improvement Effects 0.000 description 7
239000003112 inhibitor Substances 0.000 description 7
230000005764 inhibitory process Effects 0.000 description 7
230000000977 initiatory effect Effects 0.000 description 7
230000003447 ipsilateral effect Effects 0.000 description 7
238000012417 linear regression Methods 0.000 description 7
230000004060 metabolic process Effects 0.000 description 7
229960001344 methylphenidate Drugs 0.000 description 7
230000037230 mobility Effects 0.000 description 7
108090000623 proteins and genes Proteins 0.000 description 7
230000007958 sleep Effects 0.000 description 7
210000002700 urine Anatomy 0.000 description 7
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
206010061818 Disease progression Diseases 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
230000005750 disease progression Effects 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
230000003291 dopaminomimetic effect Effects 0.000 description 6
229960003337 entacapone Drugs 0.000 description 6
238000007917 intracranial administration Methods 0.000 description 6
-1 isomers Chemical compound 0.000 description 6
230000007774 longterm Effects 0.000 description 6
239000011159 matrix material Substances 0.000 description 6
230000036651 mood Effects 0.000 description 6
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 6
229940100688 oral solution Drugs 0.000 description 6
230000035699 permeability Effects 0.000 description 6
230000000284 resting effect Effects 0.000 description 6
238000010825 rotarod performance test Methods 0.000 description 6
238000005303 weighing Methods 0.000 description 6
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
102000004506 Blood Proteins Human genes 0.000 description 5
108010017384 Blood Proteins Proteins 0.000 description 5
102100034343 Integrase Human genes 0.000 description 5
241000124008 Mammalia Species 0.000 description 5
208000007101 Muscle Cramp Diseases 0.000 description 5
208000002740 Muscle Rigidity Diseases 0.000 description 5
208000025966 Neurological disease Diseases 0.000 description 5
101710138657 Neurotoxin Proteins 0.000 description 5
208000025535 REM sleep behavior disease Diseases 0.000 description 5
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 5
230000000202 analgesic effect Effects 0.000 description 5
229960004205 carbidopa Drugs 0.000 description 5
TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 description 5
238000013401 experimental design Methods 0.000 description 5
230000002440 hepatic effect Effects 0.000 description 5
238000005259 measurement Methods 0.000 description 5
238000001000 micrograph Methods 0.000 description 5
230000001095 motoneuron effect Effects 0.000 description 5
239000002581 neurotoxin Substances 0.000 description 5
231100000618 neurotoxin Toxicity 0.000 description 5
229960002748 norepinephrine Drugs 0.000 description 5
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
230000037361 pathway Effects 0.000 description 5
230000036470 plasma concentration Effects 0.000 description 5
239000013641 positive control Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
235000018102 proteins Nutrition 0.000 description 5
102000004169 proteins and genes Human genes 0.000 description 5
201000002859 sleep apnea Diseases 0.000 description 5
238000011272 standard treatment Methods 0.000 description 5
231100000331 toxic Toxicity 0.000 description 5
230000002588 toxic effect Effects 0.000 description 5
IIYCFYBNWUGFSA-RGMNGODLSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;hydrochloride Chemical compound Cl.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 IIYCFYBNWUGFSA-RGMNGODLSA-N 0.000 description 4
241000282693 Cercopithecidae Species 0.000 description 4
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 4
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 4
108010044467 Isoenzymes Proteins 0.000 description 4
238000011887 Necropsy Methods 0.000 description 4
208000002193 Pain Diseases 0.000 description 4
239000002202 Polyethylene glycol Substances 0.000 description 4
241000288906 Primates Species 0.000 description 4
206010062237 Renal impairment Diseases 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
230000003187 abdominal effect Effects 0.000 description 4
230000009471 action Effects 0.000 description 4
230000000840 anti-viral effect Effects 0.000 description 4
230000002567 autonomic effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
230000030833 cell death Effects 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
230000029142 excretion Effects 0.000 description 4
210000003414 extremity Anatomy 0.000 description 4
210000001035 gastrointestinal tract Anatomy 0.000 description 4
238000003364 immunohistochemistry Methods 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000004615 ingredient Substances 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
230000007659 motor function Effects 0.000 description 4
210000003205 muscle Anatomy 0.000 description 4
230000000966 norepinephrine reuptake Effects 0.000 description 4
239000003402 opiate agonist Substances 0.000 description 4
210000000056 organ Anatomy 0.000 description 4
230000000144 pharmacologic effect Effects 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
230000002265 prevention Effects 0.000 description 4
150000003384 small molecules Chemical class 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
230000035900 sweating Effects 0.000 description 4
HMJIYCCIJYRONP-UHFFFAOYSA-N (+-)-Isradipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)C1C1=CC=CC2=NON=C12 HMJIYCCIJYRONP-UHFFFAOYSA-N 0.000 description 3
241000283690 Bos taurus Species 0.000 description 3
101150071146 COX2 gene Proteins 0.000 description 3
101100114534 Caenorhabditis elegans ctc-2 gene Proteins 0.000 description 3
102000006378 Catechol O-methyltransferase Human genes 0.000 description 3
108020002739 Catechol O-methyltransferase Proteins 0.000 description 3
102000015554 Dopamine receptor Human genes 0.000 description 3
108050004812 Dopamine receptor Proteins 0.000 description 3
208000000059 Dyspnea Diseases 0.000 description 3
206010013975 Dyspnoeas Diseases 0.000 description 3
208000027534 Emotional disease Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
241000725303 Human immunodeficiency virus Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 3
206010028347 Muscle twitching Diseases 0.000 description 3
101150000187 PTGS2 gene Proteins 0.000 description 3
206010033664 Panic attack Diseases 0.000 description 3
208000005392 Spasm Diseases 0.000 description 3
241000282887 Suidae Species 0.000 description 3
230000008484 agonism Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
230000006736 behavioral deficit Effects 0.000 description 3
231100000871 behavioral problem Toxicity 0.000 description 3
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
229960000074 biopharmaceutical Drugs 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
238000004113 cell culture Methods 0.000 description 3
210000003169 central nervous system Anatomy 0.000 description 3
238000011260 co-administration Methods 0.000 description 3
230000021615 conjugation Effects 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
238000012377 drug delivery Methods 0.000 description 3
230000009977 dual effect Effects 0.000 description 3
230000004438 eyesight Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
230000009246 food effect Effects 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000036541 health Effects 0.000 description 3
238000000338 in vitro Methods 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
208000019423 liver disease Diseases 0.000 description 3
238000007726 management method Methods 0.000 description 3
230000007246 mechanism Effects 0.000 description 3
230000010534 mechanism of action Effects 0.000 description 3
230000003278 mimic effect Effects 0.000 description 3
229960005181 morphine Drugs 0.000 description 3
210000000653 nervous system Anatomy 0.000 description 3
230000001537 neural effect Effects 0.000 description 3
238000011859 neuroprotective therapy Methods 0.000 description 3
230000008520 organization Effects 0.000 description 3
230000036407 pain Effects 0.000 description 3
208000019906 panic disease Diseases 0.000 description 3
239000002243 precursor Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
208000013220 shortness of breath Diseases 0.000 description 3
238000009097 single-agent therapy Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
MIQPIUSUKVNLNT-UHFFFAOYSA-N tolcapone Chemical compound C1=CC(C)=CC=C1C(=O)C1=CC(O)=C(O)C([N+]([O-])=O)=C1 MIQPIUSUKVNLNT-UHFFFAOYSA-N 0.000 description 3
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 description 2
206010001541 Akinesia Diseases 0.000 description 2
PNEYBMLMFCGWSK-UHFFFAOYSA-N Alumina Chemical compound [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
208000017667 Chronic Disease Diseases 0.000 description 2
206010010904 Convulsion Diseases 0.000 description 2
206010011971 Decreased interest Diseases 0.000 description 2
206010013710 Drug interaction Diseases 0.000 description 2
206010049119 Emotional distress Diseases 0.000 description 2
241000283086 Equidae Species 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010019196 Head injury Diseases 0.000 description 2
208000010496 Heart Arrest Diseases 0.000 description 2
208000016988 Hemorrhagic Stroke Diseases 0.000 description 2
206010020565 Hyperaemia Diseases 0.000 description 2
206010021143 Hypoxia Diseases 0.000 description 2
UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
206010022998 Irritability Diseases 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 2
206010027940 Mood altered Diseases 0.000 description 2
229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
229940127450 Opioid Agonists Drugs 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
102000004316 Oxidoreductases Human genes 0.000 description 2
108090000854 Oxidoreductases Proteins 0.000 description 2
239000004372 Polyvinyl alcohol Substances 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
208000004756 Respiratory Insufficiency Diseases 0.000 description 2
206010038678 Respiratory depression Diseases 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
230000002411 adverse Effects 0.000 description 2
239000000556 agonist Substances 0.000 description 2
239000003708 ampul Substances 0.000 description 2
230000036592 analgesia Effects 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
229960004046 apomorphine Drugs 0.000 description 2
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 2
230000004888 barrier function Effects 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
239000000969 carrier Substances 0.000 description 2
YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
230000005779 cell damage Effects 0.000 description 2
208000037887 cell injury Diseases 0.000 description 2
238000003759 clinical diagnosis Methods 0.000 description 2
230000008045 co-localization Effects 0.000 description 2
230000001149 cognitive effect Effects 0.000 description 2
239000003086 colorant Substances 0.000 description 2
230000001010 compromised effect Effects 0.000 description 2
238000013270 controlled release Methods 0.000 description 2
230000001276 controlling effect Effects 0.000 description 2
230000036461 convulsion Effects 0.000 description 2
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
230000034994 death Effects 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
230000002638 denervation Effects 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
230000009429 distress Effects 0.000 description 2
210000004002 dopaminergic cell Anatomy 0.000 description 2
210000002257 embryonic structure Anatomy 0.000 description 2
206010015037 epilepsy Diseases 0.000 description 2
230000003203 everyday effect Effects 0.000 description 2
230000005713 exacerbation Effects 0.000 description 2
210000003608 fece Anatomy 0.000 description 2
239000007888 film coating Substances 0.000 description 2
238000009501 film coating Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
230000006870 function Effects 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000023611 glucuronidation Effects 0.000 description 2
210000000548 hind-foot Anatomy 0.000 description 2
238000013427 histology analysis Methods 0.000 description 2
230000001660 hyperkinetic effect Effects 0.000 description 2
230000007954 hypoxia Effects 0.000 description 2
239000005414 inactive ingredient Substances 0.000 description 2
230000003993 interaction Effects 0.000 description 2
208000020658 intracerebral hemorrhage Diseases 0.000 description 2
238000007912 intraperitoneal administration Methods 0.000 description 2
238000011835 investigation Methods 0.000 description 2
230000001788 irregular Effects 0.000 description 2
230000000302 ischemic effect Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
238000002372 labelling Methods 0.000 description 2
201000010901 lateral sclerosis Diseases 0.000 description 2
239000007788 liquid Substances 0.000 description 2
230000003908 liver function Effects 0.000 description 2
208000004731 long QT syndrome Diseases 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000003340 mental effect Effects 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
230000037353 metabolic pathway Effects 0.000 description 2
230000000051 modifying effect Effects 0.000 description 2
230000007510 mood change Effects 0.000 description 2
208000005264 motor neuron disease Diseases 0.000 description 2
230000035772 mutation Effects 0.000 description 2
229920005615 natural polymer Polymers 0.000 description 2
210000003061 neural cell Anatomy 0.000 description 2
229940005483 opioid analgesics Drugs 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
239000000651 prodrug Substances 0.000 description 2
229940002612 prodrug Drugs 0.000 description 2
238000011321 prophylaxis Methods 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004043 responsiveness Effects 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
IYETZZCWLLUHIJ-UTONKHPSSA-N selegiline hydrochloride Chemical group [Cl-].C#CC[NH+](C)[C@H](C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UTONKHPSSA-N 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
208000020431 spinal cord injury Diseases 0.000 description 2
230000002269 spontaneous effect Effects 0.000 description 2
238000013268 sustained release Methods 0.000 description 2
239000012730 sustained-release form Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
210000001519 tissue Anatomy 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
229960004603 tolcapone Drugs 0.000 description 2
238000002723 toxicity assay Methods 0.000 description 2
230000002485 urinary effect Effects 0.000 description 2
PHJFLPMVEFKEPL-UHFFFAOYSA-N (6-methoxy-2-naphthyl)acetic acid Chemical compound C1=C(CC(O)=O)C=CC2=CC(OC)=CC=C21 PHJFLPMVEFKEPL-UHFFFAOYSA-N 0.000 description 1
ODSQODTUNULBHF-JGVFFNPUSA-N 2',3'-dehydro-2',3'-deoxy-thymidine 5'-triphosphate Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO[P@@](O)(=O)O[P@](O)(=O)OP(O)(O)=O)O1 ODSQODTUNULBHF-JGVFFNPUSA-N 0.000 description 1
LOWWSYWGAKCKLG-UHFFFAOYSA-N 2-(6-methoxynaphthalen-1-yl)acetic acid Chemical compound OC(=O)CC1=CC=CC2=CC(OC)=CC=C21 LOWWSYWGAKCKLG-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 description 1
PQQINTFVECNXLC-UHFFFAOYSA-N 3-[2-methyl-1-(methylamino)pentan-3-yl]phenol Chemical compound CNCC(C)C(CC)C1=CC=CC(O)=C1 PQQINTFVECNXLC-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
230000035502 ADME Effects 0.000 description 1
206010000125 Abnormal dreams Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
101100496968 Caenorhabditis elegans ctc-1 gene Proteins 0.000 description 1
229940127291 Calcium channel antagonist Drugs 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
102100039511 Chymotrypsin-C Human genes 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
206010010774 Constipation Diseases 0.000 description 1
229920002785 Croscarmellose sodium Polymers 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
208000020401 Depressive disease Diseases 0.000 description 1
229920001353 Dextrin Polymers 0.000 description 1
239000004375 Dextrin Substances 0.000 description 1
101100027815 Drosophila melanogaster a10 gene Proteins 0.000 description 1
206010052804 Drug tolerance Diseases 0.000 description 1
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
101000889306 Homo sapiens Chymotrypsin-C Proteins 0.000 description 1
101000801195 Homo sapiens TLE family member 5 Proteins 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010020880 Hypertrophy Diseases 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
206010065611 Intestinal congestion Diseases 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
102000008109 Mixed Function Oxygenases Human genes 0.000 description 1
108010074633 Mixed Function Oxygenases Proteins 0.000 description 1
229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
208000016285 Movement disease Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
206010028813 Nausea Diseases 0.000 description 1
206010056677 Nerve degeneration Diseases 0.000 description 1
208000036110 Neuroinflammatory disease Diseases 0.000 description 1
101100221647 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cox-1 gene Proteins 0.000 description 1
206010029350 Neurotoxicity Diseases 0.000 description 1
229940121954 Opioid receptor agonist Drugs 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
235000007164 Oryza sativa Nutrition 0.000 description 1
101150053185 P450 gene Proteins 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150062589 PTGS1 gene Proteins 0.000 description 1
206010033864 Paranoia Diseases 0.000 description 1
208000027099 Paranoid disease Diseases 0.000 description 1
208000027089 Parkinsonian disease Diseases 0.000 description 1
206010056242 Parkinsonian gait Diseases 0.000 description 1
206010034010 Parkinsonism Diseases 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
241000070023 Phoenicopterus roseus Species 0.000 description 1
206010067206 Postural reflex impairment Diseases 0.000 description 1
102000004257 Potassium Channel Human genes 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
206010071390 Resting tremor Diseases 0.000 description 1
208000005793 Restless legs syndrome Diseases 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
241000238370 Sepia Species 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
206010042434 Sudden death Diseases 0.000 description 1
102000019355 Synuclein Human genes 0.000 description 1
108050006783 Synuclein Proteins 0.000 description 1
206010044221 Toxic encephalopathy Diseases 0.000 description 1
HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
108020005202 Viral DNA Proteins 0.000 description 1
241000700605 Viruses Species 0.000 description 1
206010047700 Vomiting Diseases 0.000 description 1
VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
230000036982 action potential Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000008186 active pharmaceutical agent Substances 0.000 description 1
208000005298 acute pain Diseases 0.000 description 1
230000007059 acute toxicity Effects 0.000 description 1
231100000403 acute toxicity Toxicity 0.000 description 1
230000008649 adaptation response Effects 0.000 description 1
238000011360 adjunctive therapy Methods 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
238000000540 analysis of variance Methods 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229940031774 azilect Drugs 0.000 description 1
108091008698 baroreceptors Proteins 0.000 description 1
238000003287 bathing Methods 0.000 description 1
238000010009 beating Methods 0.000 description 1
BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 1
229960000911 benserazide Drugs 0.000 description 1
GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 1
229960001081 benzatropine Drugs 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
235000021152 breakfast Nutrition 0.000 description 1
239000000480 calcium channel blocker Substances 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
235000010980 cellulose Nutrition 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000000812 cholinergic antagonist Substances 0.000 description 1
231100000085 chronic toxic effect Toxicity 0.000 description 1
238000011278 co-treatment Methods 0.000 description 1
238000000576 coating method Methods 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
229940087613 comtan Drugs 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
238000012937 correction Methods 0.000 description 1
229940111134 coxibs Drugs 0.000 description 1
229940109239 creatinine Drugs 0.000 description 1
229960005168 croscarmellose Drugs 0.000 description 1
239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
230000006378 damage Effects 0.000 description 1
239000003954 decarboxylase inhibitor Substances 0.000 description 1
238000006114 decarboxylation reaction Methods 0.000 description 1
230000003412 degenerative effect Effects 0.000 description 1
230000001934 delay Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
230000000994 depressogenic effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
235000019425 dextrin Nutrition 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
230000035487 diastolic blood pressure Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
150000002016 disaccharides Chemical class 0.000 description 1
238000011979 disease modifying therapy Methods 0.000 description 1
208000037765 diseases and disorders Diseases 0.000 description 1
230000006733 dopaminergic cell loss Effects 0.000 description 1
230000004771 dopaminergic neurodegeneration Effects 0.000 description 1
230000035622 drinking Effects 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
238000009506 drug dissolution testing Methods 0.000 description 1
230000036267 drug metabolism Effects 0.000 description 1
230000000142 dyskinetic effect Effects 0.000 description 1
230000000632 dystonic effect Effects 0.000 description 1
229940084238 eldepryl Drugs 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
210000003743 erythrocyte Anatomy 0.000 description 1
230000001815 facial effect Effects 0.000 description 1
229940057941 fd &c yellow #6 aluminum lake Drugs 0.000 description 1
239000010408 film Substances 0.000 description 1
210000003811 finger Anatomy 0.000 description 1
238000010579 first pass effect Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013312 flour Nutrition 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000021471 food effect Nutrition 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
230000030135 gastric motility Effects 0.000 description 1
208000037870 generalized anxiety Diseases 0.000 description 1
230000024924 glomerular filtration Effects 0.000 description 1
229940097043 glucuronic acid Drugs 0.000 description 1
229930182480 glucuronide Natural products 0.000 description 1
150000008134 glucuronides Chemical class 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
238000009499 grossing Methods 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
230000026781 habituation Effects 0.000 description 1
210000004247 hand Anatomy 0.000 description 1
230000010224 hepatic metabolism Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
239000012510 hollow fiber Substances 0.000 description 1
102000056245 human TLE5 Human genes 0.000 description 1
229920001477 hydrophilic polymer Polymers 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
229940090411 ifex Drugs 0.000 description 1
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
201000001881 impotence Diseases 0.000 description 1
238000012606 in vitro cell culture Methods 0.000 description 1
238000010874 in vitro model Methods 0.000 description 1
238000012750 in vivo screening Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
239000013038 irreversible inhibitor Substances 0.000 description 1
229960004427 isradipine Drugs 0.000 description 1
210000003127 knee Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
229960001021 lactose monohydrate Drugs 0.000 description 1
210000002414 leg Anatomy 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
231100000636 lethal dose Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000006738 locomotor deficit Effects 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
235000018977 lysine Nutrition 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
235000012054 meals Nutrition 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
239000003697 methyltransferase inhibitor Substances 0.000 description 1
230000003228 microsomal effect Effects 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
230000037023 motor activity Effects 0.000 description 1
239000012120 mounting media Substances 0.000 description 1
210000002200 mouth mucosa Anatomy 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
229960004127 naloxone Drugs 0.000 description 1
239000003887 narcotic antagonist Substances 0.000 description 1
229920001206 natural gum Polymers 0.000 description 1
239000006225 natural substrate Substances 0.000 description 1
230000008693 nausea Effects 0.000 description 1
229940020452 neupro Drugs 0.000 description 1
230000003959 neuroinflammation Effects 0.000 description 1
230000000926 neurological effect Effects 0.000 description 1
230000002981 neuropathic effect Effects 0.000 description 1
239000004090 neuroprotective agent Substances 0.000 description 1
230000001928 neurorestorative effect Effects 0.000 description 1
230000002887 neurotoxic effect Effects 0.000 description 1
231100000228 neurotoxicity Toxicity 0.000 description 1
230000007135 neurotoxicity Effects 0.000 description 1
239000002858 neurotransmitter agent Substances 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 1
230000012154 norepinephrine uptake Effects 0.000 description 1
229940083311 nucynta Drugs 0.000 description 1
229940099990 ogen Drugs 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000001543 one-way ANOVA Methods 0.000 description 1
239000000014 opioid analgesic Substances 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000010355 oscillation Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229940052740 other dopaminergic agent in atc Drugs 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
230000005019 pattern of movement Effects 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
238000011056 performance test Methods 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
238000011170 pharmaceutical development Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
238000011176 pooling Methods 0.000 description 1
230000000270 postfertilization Effects 0.000 description 1
108020001213 potassium channel Proteins 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229940069328 povidone Drugs 0.000 description 1
FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
210000001774 pressoreceptor Anatomy 0.000 description 1
230000008569 process Effects 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
150000003180 prostaglandins Chemical class 0.000 description 1
230000004224 protection Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000000541 pulsatile effect Effects 0.000 description 1
238000004080 punching Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
238000013102 re-test Methods 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000036279 refractory period Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
235000009566 rice Nutrition 0.000 description 1
238000011808 rodent model Methods 0.000 description 1
KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 description 1
239000004576 sand Substances 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
208000002131 short QT syndrome Diseases 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
235000020183 skimmed milk Nutrition 0.000 description 1
230000005061 slumber Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
239000008279 sol Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000012453 solvate Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
241000894007 species Species 0.000 description 1
230000008925 spontaneous activity Effects 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
230000035882 stress Effects 0.000 description 1
208000023516 stroke disease Diseases 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
208000011117 substance-related disease Diseases 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000005846 sugar alcohols Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
230000001502 supplementing effect Effects 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000002889 sympathetic effect Effects 0.000 description 1
210000000225 synapse Anatomy 0.000 description 1
230000015883 synaptic transmission, dopaminergic Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000035488 systolic blood pressure Effects 0.000 description 1
229940000238 tasmar Drugs 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
238000004448 titration Methods 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
238000003325 tomography Methods 0.000 description 1
231100000440 toxicity profile Toxicity 0.000 description 1
238000012546 transfer Methods 0.000 description 1
229960001032 trihexyphenidyl Drugs 0.000 description 1
230000010248 tubular secretion Effects 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
238000011870 unpaired t-test Methods 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
230000000007 visual effect Effects 0.000 description 1
230000008673 vomiting Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940068543 zelapar Drugs 0.000 description 1
229940087450 zerit Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Neurosurgery (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Emergency Medicine (AREA)
Psychology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CA2986891A 2015-05-26 2016-05-25 Compositions et methodes pour le traitement de la maladie de parkinson et de troubles associes Active CA2986891C (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562166531P	2015-05-26	2015-05-26
US62/166,531		2015-05-26
PCT/PT2016/050010 WO2016190766A1 (fr)	2015-05-26	2016-05-25	Compositions et méthodes pour le traitement de la maladie de parkinson et de troubles associés

Publications (2)

Publication Number	Publication Date
CA2986891A1 true CA2986891A1 (fr)	2016-12-01
CA2986891C CA2986891C (fr)	2022-01-04

Family

ID=56322267

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA2986891A Active CA2986891C (fr)	2015-05-26	2016-05-25	Compositions et methodes pour le traitement de la maladie de parkinson et de troubles associes

Country Status (9)

Country	Link
US (1)	US10471025B2 (fr)
EP (1)	EP3302454B1 (fr)
JP (1)	JP6853791B2 (fr)
CN (1)	CN107660147B (fr)
AU (1)	AU2016266432B2 (fr)
CA (1)	CA2986891C (fr)
ES (1)	ES2869981T3 (fr)
PT (1)	PT3302454T (fr)
WO (1)	WO2016190766A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL319386A (en) *	2018-10-11	2025-05-01	Indivior Uk Ltd	Buprenorphine for the treatment of respiratory depression
EP3902539B1 (fr) *	2018-12-24	2024-07-31	Sorrento Therapeutics, Inc.	Méthodes pour traiter la maladie de parkinson par administration de résinifératoxine
EP4243801A1 (fr) *	2020-11-10	2023-09-20	Integrative Research Laboratories Sweden AB	[2-(3-fluoro-5-méthanesulfonylphénoxy)éthyl](propyl)amine (mesdopetam) pour une utilisation dans la prévention ou la réduction de la sensibilisation à un médicament pharmaceutique pour la maladie de parkinson, en particulier les dyskinésies induites par l-dopa
CN112933117B (zh) *	2021-04-28	2023-04-07	遵义医科大学	一种预防和/或治疗帕金森病的药物及其应用
JP2024520132A (ja) *	2021-06-04	2024-05-21	トランスポゾンセラピューティクスインコーポレイテッド	向知性薬としてのｌｉｎｅ－１阻害剤
CN113422876B (zh) *	2021-06-24	2022-05-10	广西电网有限责任公司	基于ai的电力客服中心辅助管理方法、系统及介质
WO2023019351A1 (fr) *	2021-08-16	2023-02-23	University Health Network	Méthodes et compositions pour le traitement de la neurodégénérescence induite par l'alpha-synucléine
CN116832066B (zh) *	2023-08-08	2024-01-12	青岛海洋生物医药研究院股份有限公司	乌贼墨提取物在制备抗多动症和抗抑郁症药物中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6071970A (en)	1993-02-08	2000-06-06	Nps Pharmaceuticals, Inc.	Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
DE4426245A1 (de)	1994-07-23	1996-02-22	Gruenenthal Gmbh	1-Phenyl-3-dimethylamino-propanverbindungen mit pharmakologischer Wirkung
PT1539135E (pt) *	2002-09-17	2007-07-12	Motac Neuroscience Ltd	Tratamento da discinesia.
WO2008079404A2 (fr)	2006-12-22	2008-07-03	Combinatorx, Incorporated	Compositions pharmaceutiques pour le traitement de la maladie de parkinson et de troubles apparentés
EP1985292A1 (fr) *	2007-04-23	2008-10-29	Grünenthal GmbH	Titrage de tapentadol
PL2596784T3 (pl) *	2007-11-23	2017-06-30	Grünenthal GmbH	Kompozycje tapentadolu
WO2009147681A1 (fr)	2008-06-06	2009-12-10	Pharma Two B Ltd.	Compositions pharmaceutiques pour le traitement de la maladie de parkinson
US8288592B2 (en)	2009-09-22	2012-10-16	Actavis Group Ptc Ehf	Solid state forms of tapentadol salts
US20140037729A1 (en) *	2010-12-28	2014-02-06	Euro-Celtique, S.A.	Combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
WO2012136351A1 (fr) *	2011-04-05	2012-10-11	Grünenthal GmbH	Tapentadol utilisé dans le traitement de la douleur associée à une névralgie faciale
PT2701693T (pt) *	2011-04-29	2017-11-16	Gruenenthal Gmbh	Tapentadol para prevenção e tratamento de depressão e ansiedade
KR20240004497A (ko) *	2013-03-15	2024-01-11	멜리어 파마슈티칼스 투, 엘엘씨.	시드노카브 또는 이의 약학적으로 허용되는 염을 포함하는 약학적 조성물 및 수면 장애를 치료하는 방법

2016
- 2016-05-25 US US15/568,655 patent/US10471025B2/en active Active
- 2016-05-25 PT PT167344811T patent/PT3302454T/pt unknown
- 2016-05-25 EP EP16734481.1A patent/EP3302454B1/fr active Active
- 2016-05-25 WO PCT/PT2016/050010 patent/WO2016190766A1/fr not_active Ceased
- 2016-05-25 AU AU2016266432A patent/AU2016266432B2/en active Active
- 2016-05-25 CA CA2986891A patent/CA2986891C/fr active Active
- 2016-05-25 JP JP2017559872A patent/JP6853791B2/ja active Active
- 2016-05-25 ES ES16734481T patent/ES2869981T3/es active Active
- 2016-05-25 CN CN201680030076.6A patent/CN107660147B/zh active Active

Also Published As

Publication number	Publication date
JP2018515549A (ja)	2018-06-14
AU2016266432B2 (en)	2020-10-22
CN107660147B (zh)	2021-04-30
WO2016190766A1 (fr)	2016-12-01
CA2986891C (fr)	2022-01-04
EP3302454A1 (fr)	2018-04-11
EP3302454B1 (fr)	2021-03-10
CN107660147A (zh)	2018-02-02
ES2869981T3 (es)	2021-10-26
PT3302454T (pt)	2021-04-01
US20180147160A1 (en)	2018-05-31
US10471025B2 (en)	2019-11-12
JP6853791B2 (ja)	2021-03-31
AU2016266432A1 (en)	2017-11-09

Publication	Publication Date	Title
US10471025B2 (en)	2019-11-12	Compositions for use in treating parkinson's disease and related disorders
US10799493B2 (en)	2020-10-13	Compositions and methods for treating schizophrenia
US20060122127A1 (en)	2006-06-08	Methods for reducing the side effects associated with mirtzapine treatment
AU2008266906A1 (en)	2008-12-24	Combination therapy for depression
TW200908957A (en)	2009-03-01	Use of prodrugs of GABA analogs, antispasticity agents, and prodrugs of GABAB receptor agonists for treating spasticity
US10905672B2 (en)	2021-02-02	Combination of baclofen, acamprosate and medium chain triglycerides for the treatment of neurological disorders
TW201841637A (zh)	2018-12-01	使用ccr3-抑制劑治療老化相關損傷之方法及組合物
IL298334A (en)	2023-01-01	Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders
EA015483B1 (ru)	2011-08-30	ПРИМЕНЕНИЕ ИНГИБИТОРА p38 КИНАЗЫ ДЛЯ ЛЕЧЕНИЯ ПСИХИАТРИЧЕСКИХ РАССТРОЙСТВ
Ciccone	2019	Geriatric pharmacology
JP5259181B2 (ja)	2013-08-07	うつ病または不安神経症の予防または治療剤
EP4583858A1 (fr)	2025-07-16	Combinaisons comprenant des psychédéliques pour le traitement de la schizophrénie et d'autres troubles neuropsychiatriques et neurologiques
US20150335629A1 (en)	2015-11-26	Methods Of Treating Fragile X Syndrome And Related Disorders
US11491150B2 (en)	2022-11-08	Organic compounds
US20250387382A1 (en)	2025-12-25	Methods of treating essential tremor
TW201408294A (zh)	2014-03-01	(r)-苯基披喇瑟盪於治療帕金森氏症之用除
US20240050427A1 (en)	2024-02-15	Treatments for obsessive compulsive disorder
WO2024182677A1 (fr)	2024-09-06	Méthodes de traitement du tremblement essentiel
JP2025087929A (ja)	2025-06-11	うつ病および／またはうつ状態の治療および／または予防用医薬
Standard	2022	NAME OF DRUG
US20120028976A1 (en)	2012-02-02	Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
AU2024225878A1 (en)	2025-09-04	Pharmaceutical for treating or preventing peripheral neuropathy
EP3087984B1 (fr)	2021-04-07	Agent prophylactique et thérapeutique contre le trouble du déficit de l' attention avec hyperactivité
Tablets et al.	2018	Pr MEMANTINE
US20050119283A1 (en)	2005-06-02	Treatment of circadian rhythm disorders with NPY Y5 receptor antagonist

Legal Events

Date	Code	Title	Description
2020-03-20	EEER	Examination request	Effective date: 20200306